GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...
Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at the Food and Drug ...
The firm specialises in high-specification furniture for leading universities including Cambridge and Loughborough, research ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...
Chris Beauchamp, chief market analyst at IG ... down 928p to 10,114p, Hikma Pharmaceuticals, down 36p to 1,820p, GSK, down 22 ...
GlobalData on MSN5d
GSK CEO addresses declining trust in vaccines following Trump re-electionGSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...
Robert F. Kennedy Jr is known as a persistent critic of vaccine safety and is a longtime antagonist of the Food and Drug ...
Legal-Bay LLC, the premier Pre Settlement Funding Company, reports that the ongoing legal disputes against UK pharmaceutical company GlaxoSmithKline (GSK) regarding their heartburn medicine, Zantac, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback